O
OcuMension Therapeutics
Biotech & Life Sciences · Huangpu, China · Founded 2017 · IPO 2020
Company which focuses on the development of ophthalmic medications MoreLess
Ocumension Therapeutics specializes in developing and commercializing innovative ophthalmic solutions aimed at enhancing eye health. The company operates in the pharmaceutical sector, focusing on the treatment of eye diseases and conditions. Ocumension serves a diverse range of clients, including healthcare providers, hospitals, and clinics, primarily in the Asia-Pacific region. The business model revolves around research and development, clinical trials, and the subsequent commercialization of its products. Revenue is generated through the sale of its therapeutic products and potential licensing agreements with other pharmaceutical companies.
Keywords: ophthalmic solutions, eye health, therapeutics, pharmaceutical, Asia-Pacific, healthcare providers, hospitals, clinics, research and development, commercialization.
Company overview
OcuMension Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Huangpu, China
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 35.9
- Investment activity
- 2 companies · latest Apr 2021
- Capital deployed
- —
- Preferred round
- POST IPO EQUITY
Valuation & funding
OcuMension Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Oct 2024 | $0 | — | Alcon | ↗ |
| IPOOther financing | Jul 2020 | $184M | $184M | Undisclosed | — |
| SERIES BOther financing | Jun 2019 | $180M | $720M | General Atlantic | ↗ |
| SERIES AOther financing | Feb 2019 | $20M | $80M | Undisclosed | ↗ |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $152M | +37.4% | $16M | 10.3% |
| 2025 | $111M | +92.7% | −$2M | -1.9% |
| 2024 | $57M | +69.4% | −$24M | -42.1% |
| 2023 | $34M | +55% | −$45M | -131.8% |
| 2022 | $22M | +183.1% | −$49M | -224.4% |
| 2021 | $7.7M | +328.7% | −$51M | -661.3% |
| 2020 | $1.8M | — | −$312M | -17316.6% |
Growth signals
OcuMension Therapeutics website traffic
Latest recorded traffic for OcuMension Therapeutics is 390 monthly website visits, up 34.5% over the last three months. OcuMension Therapeutics's team declined 11.5% over the past year.
Comparisons
OcuMension Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
OcuMension Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Alimera SciencesAlpharetta, United StatesDevelops and commercializes prescription ophthalmic pharmaceuticals
$360Mvaluation
EyePoint PharmaceuticalsWatertown, United StatesTiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate
$233Mvaluation
Talent graph
OcuMension Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where OcuMension Therapeutics has talent and traffic
team presence
In the news
Latest news about OcuMension Therapeutics
Recent press, funding announcements, and product moves mentioning OcuMension Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about OcuMension Therapeutics
An AI-synthesized read of the highest-engagement posts about OcuMension Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OcuMension Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.